Cyclo Therapeutics (CYTH) PT Lowered to $0.95 at Ascendiant Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
Go back to Cyclo Therapeutics (CYTH) PT Lowered to $0.95 at Ascendiant Capital
August 23, 2024 6:06 AM EDT
(Updated - August 23, 2024 6:34 AM EDT)
H.C. Wainwright analyst Swayampakula Ramakanth downgraded Cyclo Therapeutics (NASDAQ: CYTH) from Buy to Neutral with a price target of $0.95 (from $3.00).
The analyst comments "Rafael Holdings to acquire Cyclo. On August 22, Cyclo Therapeutics announced that... More
August 22, 2024 6:50 AM EDT
Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (Nasdaq: CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics shareholders, based on an exchange ratio valuing Cyclo Therapeutics shares at $.95 per share and Rafael Holdings at its cash value combined with the value of its marketable... More
